Health Canada approves Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia

2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib. ...

Read more →

Medexus announces expanded availability of Gleolan in Canada

25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...

Read more →

Bladder cancer drug shortage resolved with Health Canada approval

24 February 2021 - Verity-BCG bladder cancer treatment available for Canadian patients in the spring. ...

Read more →

Health Canada approves Imbruvica (ibrutinib) plus rituximab for the treatment of patients with chronic lymphocytic leukaemia

13 January 2021 - Patients aged 70 or younger with previously untreated CLL lived longer without disease progression compared to patients ...

Read more →

Health Canada approves Onureg (azacitidine tablets), first maintenance therapy for patients in remission from acute myeloid leukaemia

12 January 2021 - Onureg has shown clinically meaningful increase in overall survival for patients. ...

Read more →

MorphoSys and Incyte announce acceptance by Health Canada of the new drug submission for tafasitamab

12 January 2021 - MorphoSys and Incyte today announced that Health Canada has accepted the new drug submission for tafasitamab, an ...

Read more →

Health Canada approves Bavencio for the maintenance treatment of patients with advanced bladder cancer

11 January 2021 - Bavencio is the first and only maintenance therapy for unresectable locally advanced or metastatic urothelial carcinoma ...

Read more →

Janssen announces Health Canada approval of Darzalex combination regimen for newly diagnosed, transplant eligible patients with multiple myeloma

22 December 2020 - Data show Darzalex in combination with bortezomib, thalidomide and dexamethasone before and after autologous stem cell transplant ...

Read more →

Health Canada approves Venclexta (venetoclax) in combination with azacitidine or low dose cytarabine for untreated acute myeloid leukaemia

15 December 2020 - Health Canada's approval of Venclexta for newly diagnosed AML patients who are ineligible for intensive chemotherapy is ...

Read more →

Lynparza (olaparib) receives Health Canada approval for the treatment of BRCA or ATM gene-mutated metastatic castration-resistant prostate cancer

25 November 2020 - On 21 August 2020, Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious ...

Read more →

Knight Therapeutics announces filing of supplement to a new drug submission for Nerlynx (neratinib) to treat HER2-positive metastatic breast cancer

3 September 2020 - Knight Therapeutics Inc. announced filing of the supplement to a new drug submission (SNDS) of Nerlynx ...

Read more →

Novartis' MONALEESA-7 Kisqali (ribociclib succinate) study demonstrated statistically significant improvement in overall survival in pre- and peri-menopausal women with HR+/HER2- advanced breast cancer

2 November 2020 - Novartis Pharmaceuticals Canada is pleased to announce that statistically significant overall survival  results for Kisqali (ribociclib succinate) ...

Read more →

Incyte announces Health Canada acceptance of the new drug submission for pemigatinib as a treatment for patients with cholangiocarcinoma

26 October 2020 - Incyte today announced that Health Canada has accepted its new drug submission for pemigatinib, a selective fibroblast ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma

15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...

Read more →

Health Canada approves Inqovi (decitabine and cedazuridine) oral therapy for two types of blood cancers, MDS and CMML

8 October 2020 - Oral drug can be taken at home, which may enable some patients to avoid some hospital visits. ...

Read more →